BR112023023708A2 - Formulação contendo derivado de di-hidropiridazino-3,5-diona - Google Patents

Formulação contendo derivado de di-hidropiridazino-3,5-diona

Info

Publication number
BR112023023708A2
BR112023023708A2 BR112023023708A BR112023023708A BR112023023708A2 BR 112023023708 A2 BR112023023708 A2 BR 112023023708A2 BR 112023023708 A BR112023023708 A BR 112023023708A BR 112023023708 A BR112023023708 A BR 112023023708A BR 112023023708 A2 BR112023023708 A2 BR 112023023708A2
Authority
BR
Brazil
Prior art keywords
formulation containing
methyl
dione derivative
hydropyranzino
trifluoromethyl
Prior art date
Application number
BR112023023708A
Other languages
English (en)
Portuguese (pt)
Inventor
Hiromasa Uchiyama
Kenichi Sakai
Mayumi Yoshikawa
Ryusuke Takano
Shigemori Natsumoto
Tomoyuki Minoda
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112023023708A2 publication Critical patent/BR112023023708A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112023023708A 2021-06-08 2022-06-08 Formulação contendo derivado de di-hidropiridazino-3,5-diona BR112023023708A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021096206 2021-06-08
PCT/JP2022/023076 WO2022260064A1 (ja) 2021-06-08 2022-06-08 ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤

Publications (1)

Publication Number Publication Date
BR112023023708A2 true BR112023023708A2 (pt) 2024-01-30

Family

ID=84426023

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023708A BR112023023708A2 (pt) 2021-06-08 2022-06-08 Formulação contendo derivado de di-hidropiridazino-3,5-diona

Country Status (12)

Country Link
US (1) US20240293402A1 (cg-RX-API-DMAC7.html)
EP (1) EP4353233A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022260064A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240018523A (cg-RX-API-DMAC7.html)
CN (1) CN117460511A (cg-RX-API-DMAC7.html)
AU (1) AU2022288895A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023708A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221186A1 (cg-RX-API-DMAC7.html)
IL (1) IL309056A (cg-RX-API-DMAC7.html)
MX (1) MX2023014507A (cg-RX-API-DMAC7.html)
TW (1) TW202317118A (cg-RX-API-DMAC7.html)
WO (1) WO2022260064A1 (cg-RX-API-DMAC7.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012012421A (es) 2010-04-28 2012-12-17 Astellas Pharma Inc Compuestos tetrahidrobenzotiofena.
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PL2772490T3 (pl) 2011-10-27 2016-11-30 Aminoalkilo-podstawiona pochodna n-tienylobenzamidu
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
AU2014230552B2 (en) * 2013-03-13 2017-11-16 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative
US9499553B2 (en) * 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
EP4374877A3 (en) 2014-09-12 2024-07-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification.
MX376202B (es) 2016-08-15 2025-03-07 Lilly Co Eli Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
US12097204B2 (en) * 2018-09-03 2024-09-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof

Also Published As

Publication number Publication date
KR20240018523A (ko) 2024-02-13
CN117460511A (zh) 2024-01-26
MX2023014507A (es) 2024-01-26
EP4353233A1 (en) 2024-04-17
AU2022288895A1 (en) 2024-01-18
US20240293402A1 (en) 2024-09-05
IL309056A (en) 2024-02-01
TW202317118A (zh) 2023-05-01
WO2022260064A1 (ja) 2022-12-15
JPWO2022260064A1 (cg-RX-API-DMAC7.html) 2022-12-15
EP4353233A4 (en) 2025-06-25
CA3221186A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
MA59373B1 (fr) [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2
CL2011000880A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer.
WO2021012049A8 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
BR112021025458A2 (pt) Formulação farmacêutica, método de preparação e uso da mesma
UA84167C2 (ru) Производные хиназолина как ингибиторы тирозинкиназы, способ их получения (варианты), фармацевтическая композиция на их основе
CY1116490T1 (el) Φαρμακευτικες συνθεσεις κλεβιδιπινης και μεθοδοι για την παραγωγη συγκεντρωσεων χαμηλων προσμιξεων των ιδιων
MX2007012947A (es) Composiciones biomejoradas.
BR112014033055A8 (pt) Inibidores seletivos de delta pi3k
MY157871A (en) Mapk/erk kinase inhibitors
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
UA94570C2 (en) Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
WO2019202160A3 (en) A 5-thiazolecarboxamide kinase inhibitor and uses thereof
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
EA200700312A1 (ru) Композиции для доставки лекарственных средств с высокой водорастворимостью
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.
GEAP202014783A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
MX2023000577A (es) Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa.
GEP20115186B (en) Novel tricyclic derivatives, process for the preparation thereof and pharmaceutical compositions containing same
WO2024054669A3 (en) Compounds and compositions for intracellular delivery of nucleic acid-based therapeutics and methods thereof
PE20232046A1 (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
DK1635792T3 (da) Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater
MX2023010083A (es) Derivados heterociclicos como inhibidores de cinasas jano.
TWI908843B (zh) 水性組成物